Skip to main content

Table 1 Incidence of first cervical HPVI, 6MPI, CIN1+ and CIN2+

From: Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial

HPV type

HPVI (N = 496)

6MPI (N = 281)

CIN1+ (N = 50)

CIN2+ (N = 29)

 

n (%)

Incidence per 100 PY (95% CI) 1

n (%)

Incidence per 100 PY (95% CI) 1

n (%)

Incidence per 100 PY (95% CI) 1

n (%)

Incidence per 100 PY (95% CI) 1

All

496 (50.5)2

27.08 (24.75-29.57)

281 (28.6)2

13.29 (11.78-14.94)

50 (5.1)2

1.87 (1.39-2.46)

29 (3.0)2

1.07 (0.72-1.54)

Oncogenic HPV types

16

90 (18.2)

4.91 (3.95-6.04)

58 (20.6)

2.74 (2.08-3.55)

22 (44.0)

0.82 (0.52-1.24)

17 (58.6)

0.63 (0.37-1.01)

18

50 (10.1)

2.73 (2.03-3.60)

23 (8.2)

1.09 (0.69-1.63)

3 (6.0)

0.11 (0.02-0.33)

2 (6.9)

0.07 (0.01-0.27)

31

32 (6.5)

1.75 (1.20-2.47)

19 (6.8)

0.90 (0.54-1.40)

6 (12.0)

0.22 (0.08-0.49)

2 (6.9)

0.07 (0.01-0.27)

33

21 (4.2)

1.15 (0.71-1.75)

10 (3.6)

0.47 (0.23-0.87)

4 (8.0)

0.15 (0.04-0.38)

3 (10.3)

0.11 (0.02-0.32)

35

9 (1.8)

0.49 (0.22-0.93)

3 (1.1)

0.14 (0.03-0.41)

1 (2.0)

0.04 (0.00-0.21)

0

0.00 (0.00-0.14)

39

34 (6.9)

1.86 (1.29-2.59)

20 (7.1)

0.95 (0.58-1.46)

3 (6.0)

0.11 (0.02-0.33)

2 (6.9)

0.07 (0.01-0.27)

45

22 (4.4)

1.20 (0.75-1.82)

6 (2.1)

0.28 (0.10-0.62)

1 (2.0)

0.04 (0.00-0.21)

0

0.00 (0.00-0.14)

51

109 (22.0)

5.95 (4.89-7.18)

57 (20.3)

2.70 (2.04-3.49)

7 (14.0)

0.26 (0.11-0.54)

4 (13.8)

0.15 (0.04-0.38)

52

61 (12.3)

3.33 (2.55-4.28)

35 (12.5)

1.66 (1.15-2.30)

4 (8.0)

0.15 (0.04-0.38)

2 (6.9)

0.07 (0.01-0.27)

56

44 (8.9)

2.40 (1.75-3.23)

19 (6.8)

0.90 (0.54-1.40)

5 (10.0)

0.19 (0.06-0.44)

3 (10.3)

0.11 (0.02-0.32)

58

22 (4.4)

1.20 (0.75-1.82)

14 (5.0)

0.66 (0.36-1.11)

7 (14.0)

0.26 (0.11-0.54)

2 (6.9)

0.07 (0.01-0.27)

59

26 (5.2)

1.42 (0.93-2.08)

1 (0.4)

0.05 (0.00-0.26)

0

0.00 (0.00-0.14)

0

0.00 (0.00-0.14)

66

46 (9.3)

2.51 (1.84-3.35)

24 (8.5)

1.14 (0.73-1.69)

4 (8.0)

0.15 (0.04-0.38)

1 (3.5)

0.04 (0.00-0.21)

68

37 (7.5)

2.02 (1.42-2.78)

17 (6.1)

0.80 (0.47-1.29)

4 (8.0)

0.15 (0.04-0.38)

3 (10.3)

0.11 (0.02-0.32)

At least 1 oncogenic type

399 (80.4)

21.79 (19.70-24.03)

232 (82.6)

10.97 (9.61-12.48)

50 (100.0)

1.87 (1.39-2.46)

29 (100)

1.07 (0.72-1.54)

Non-oncogenic HPV types

6

74 (14.9)

4.04 (3.17-5.07)

21 (7.5)

0.99 (0.61-1.52)

3 (6.0)

0.11 (0.02-0.33)

1 (3.5)

0.04 (0.00-0.21)

11

9 (1.8)

0.49 (0.22-0.93)

1 (0.4)

0.05 (0.00-0.26)

2 (4.0)

0.07 (0.01-0.27)

0

0.00 (0.00-0.14)

34

7 (1.4)

0.38 (0.15-0.79)

1 (0.4)

0.05 (0.00-0.26)

0

0.00 (0.00-0.14)

0

0.00 (0.00-0.14)

40

16 (3.2)

0.87 (0.50-1.42)

1 (0.4)

0.05 (0.00-0.26)

2 (4.0)

0.07 (0.01-0.27)

1 (3.5)

0.04 (0.00-0.21)

42

7 (1.4)

0.38 (0.15-0.79)

0

0.00 (0.00-0.17)

0

0.00 (0.00-0.14)

0

0.00 (0.00-0.14)

43

27 (5.4)

1.47 (0.97-2.14)

3 (1.1)

0.14 (0.03-0.41)

0

0.00 (0.00-0.14)

0

0.00 (0.00-0.14)

44

4 (0.8)

0.22 (0.06-0.56)

1 (0.4)

0.05 (0.00-0.26)

0

0.00 (0.00-0.14)

0

0.00 (0.00-0.14)

53

56 (11.3)

3.06 (2.31-3.97)

28 (10.0)

1.32 (0.88-1.91)

3 (6.0)

0.11 (0.02-0.33)

2 (6.9)

0.07 (0.01-0.27)

54

16 (3.2)

0.87 (0.50-1.42)

8 (2.9)

0.38 (0.16-0.75)

3 (6.0)

0.11 (0.02-0.33)

2 (6.9)

0.07 (0.01-0.27)

70

6 (1.2)

0.33 (0.12-0.71)

6 (2.1)

0.28 (0.10-0.62)

1 (2.0)

0.04 (0.00-0.21)

0

0.00 (0.00-0.14)

74

13 (2.6)

0.71 (0.38-1.21)

6 (2.1)

0.28 (0.10-0.62)

0

0.00 (0.00-0.14)

0

0.00 (0.00-0.14)

Only non-oncogenic type

97 (19.6)

5.30 (4.29-6.46)

49 (17.4)

2.32 (1.71-3.06)

0

0.00 (0.00-0.14)

0

0.00 (0.00-0.14)

  1. 1Number of person-years: 1831.46 (HPVI); 2114.51 (6MPI); 2676.71 (CIN1+); 2703.47 (CIN2+).
  2. 2 N = 982.
  3. Some women experienced concomitant HPV infections, concomitant CIN lesions and/or CIN lesions associated with more than 1 HPV type. Therefore the number of observations for each individual HPV type do not add up to the total number of women experiencing an infection or lesion (N).
  4. 6MPI: 6-month persistent HPV infection; CI: confidence interval; CIN: cervical intraepithelial neoplasia; HPV: human papillomavirus; HPVI: HPV infection of any duration; PY: person-years.